CRSP

CRISPR Therapeutics AG

CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.

CRISPR Therapeutics AG (CRSP) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Value (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
C-
Factor Score 1.9 / 5.0
Growth
B+
Factor Score 3.7 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
C+
Factor Score 2.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -12.3
EV / EBITDA -5.8
Rev Growth YoY N/M
Gross Margin 0.0%
Price Return 3M -16.4%
Price Return 12M -18.1%
Catalyst Signal 0.00
Market Cap $4.4B
TTM Revenue $25.2M
Price / Sales 174.0
ROE -25.6%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C- (1.9) B+ (3.7) C- (1.9) C+ (2.7) C+ (2.6) C+ (2.6)
2026-11-04 D- (0.9) B+ (3.8) D+ (1.8) B- (3.0) C+ (2.7) C (2.4)
2026-10-28 D- (0.9) B+ (3.7) D+ (1.8) B- (2.9) C+ (2.7) C (2.4)
2026-10-21 D- (1.0) B+ (3.7) D+ (1.8) B- (2.9) C+ (2.6) C (2.4)
2026-10-14 D- (1.0) B+ (3.7) D+ (1.8) C+ (2.5) C+ (2.6) C (2.3)
Page 1 of 8
…